leadf
logo-loader
viewMedexus Pharmaceuticals Inc
(
TSX-V:MDPOTCQX:MEDXF
)

Full interview: Discovery Investment Research analyst says Medexus Pharmaceuticals has a solid business

James Gentrup, Senior Equity Analyst at micro-cap research firm Discovery Investment Research tells Proactive he thinks Canada-based Medexus Pharmaceuticals Inc (TSXV:MDP) (OTCQB:PDDPF) has a "solid" business with the company's single-dose auto-injector of methotrexate for the treatment of rheumatoid arthritis, and rates the company as a Speculative Buy with a price target of $7.65.

Gentrup says Medexus is one of only two major players who can deliver methotrexate to rheumatoid arthritis patients through its auto-injector method, and is impressed by the company's sales strategy to penetrate the US and Canadian markets.

Quick facts: Medexus Pharmaceuticals Inc

Follow
TSX-V:MDP

Price: - -

Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Medexus Pharmaceuticals reveals record quarterly revenue of C$31.5M

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) CEO Ken d’Entremont tells Proactive its fiscal third quarter results revealed record quarterly revenue of C$31.5M, nearly doubling its revenue year-over-year from C$16.2M in the same period in 2019. d’Entremont added given significant share...

on 03/02/2021

2 min read